Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology, vol.358, issue.5 pt 1, pp.286-293, 2009. ,
DOI : 10.1002/ana.21577
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.973-976, 2006. ,
DOI : 10.1136/jnnp.2005.081547
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies, Neurology, vol.54, issue.4, pp.943-949, 2002. ,
DOI : 10.1212/WNL.54.4.943
Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?, Journal of Neurology, vol.118, issue.1, pp.256-1876, 2009. ,
DOI : 10.1007/s00415-009-5217-0
Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies, Journal of the Neurological Sciences, vol.220, issue.1-2, pp.127-129, 2004. ,
DOI : 10.1016/j.jns.2004.03.012
Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M, Journal of the Peripheral Nervous System, vol.322, issue.2, pp.102-107, 2007. ,
DOI : 10.1212/01.wnl.0000201193.00382.b3
Rituximab for polyneuropathy with IgM monoclonal gammopathy, J Neurol Neurosurg Psychiatry, vol.80, issue.9, pp.1036-1039, 2009. ,